{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:08:09Z","timestamp":1787846889615,"version":"build-2784847793"},"reference-count":129,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Long-term survival (LTS) in multiple myeloma (MM), defined as survival of \u226510 years after diagnosis following a single line of therapy, is an increasingly observed outcome due to significant therapeutic advancements. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, autologous stem cell transplantation, and novel immunotherapies has transformed MM treatment. Importantly, only a subset of patients achieves long-term, durable disease control, suggesting that both myeloma-intrinsic and immune-mediated mechanisms play critical roles. Therapeutic advancements, including chimeric antigen receptor T-cell therapy and bispecific antibodies, have primarily benefited standard-risk patients. Beyond therapeutic interventions, LTS appears to be driven by distinct features of the immune bone marrow environment (IBME), in which enhanced T-cell function, increased natural killer cell cytotoxicity, and reduced immunosuppressive myeloid populations contribute to disease control. Understanding these immune adaptations in LTS MM provides a foundation for developing next-generation treatment strategies. Future research integrating genomic and immune profiling, along with IBME modulation, will be critical in shifting MM treatment paradigms from disease management to sustained remission and functional cures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016829","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:38:50Z","timestamp":1752784730000},"page":"5134-5147","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Molecular and immunological determinants of long-term survival in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Khanmi","family":"Kasomva","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"2Hematopoiesis and Immunology Program, Versiti Blood Research Institute, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kritika","family":"Yadav","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-5511","authenticated-orcid":false,"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2688-9541","authenticated-orcid":false,"given":"Sridhar","family":"Rao","sequence":"additional","affiliation":[{"name":"2Hematopoiesis and Immunology Program, Versiti Blood Research Institute, Milwaukee, WI"},{"name":"3Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Division of Hematology\/Oncology\/Transplantation, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"1","key":"2025102810214826100_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2025102810214826100_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33696\/haematology.4.055","article-title":"Analysis of updates in multiple myeloma treatment and management","volume":"4","author":"Nieto","year":"2023","journal-title":"J Clin Haematol"},{"issue":"3","key":"2025102810214826100_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/0008-5472.CAN-22-2654","article-title":"Deep learning enables spatial mapping of the mosaic microenvironment of myeloma bone marrow trephine biopsies","volume":"84","author":"Hagos","year":"2024","journal-title":"Cancer Res"},{"issue":"8","key":"2025102810214826100_bib4","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"2025102810214826100_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025102810214826100_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-024-01062-2","article-title":"Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"2025102810214826100_bib7","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025102810214826100_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clml.2024.11.001","article-title":"Characteristics and treatment patterns of long-surviving patients with multiple myeloma: over 13 years of follow-up in the connect MM registry","volume":"25","author":"Terebelo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025102810214826100_bib9","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2025102810214826100_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025102810214826100_bib11","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1038\/s41467-024-54543-0","article-title":"Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy","volume":"15","author":"Lutz","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"2025102810214826100_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025102810214826100_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: the green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"2025102810214826100_bib14","doi-asserted-by":"crossref","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"issue":"15","key":"2025102810214826100_bib15","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"10192","key":"2025102810214826100_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2025102810214826100_bib17","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10214","key":"2025102810214826100_bib18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"2025102810214826100_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2025102810214826100_bib20","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"2025102810214826100_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"2025102810214826100_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2025102810214826100_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2025102810214826100_bib24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10068","key":"2025102810214826100_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"2025102810214826100_bib26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2025102810214826100_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"17","key":"2025102810214826100_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2025102810214826100_bib29","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"2025102810214826100_bib30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"issue":"19","key":"2025102810214826100_bib31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2025102810214826100_bib32","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2025102810214826100_bib33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2025102810214826100_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2025102810214826100_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025102810214826100_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025102810214826100_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2025102810214826100_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2025102810214826100_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2025102810214826100_bib40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025102810214826100_bib41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2025102810214826100_bib42","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.clml.2025.01.009","article-title":"Real-world treatment patterns and outcomes in patients with lenalidomide-refractory multiple myeloma with 1 to 3 prior lines: SEER-Medicare database","volume":"25","author":"Dhakal","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2025102810214826100_bib43","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025102810214826100_bib44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"issue":"24","key":"2025102810214826100_bib45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2025102810214826100_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000543265","article-title":"Novel approaches of cellular therapy in multiple myeloma: focus on chimeric antigen receptor T-cells","volume":"148","author":"Narra","year":"2025","journal-title":"Acta Haematol"},{"issue":"7","key":"2025102810214826100_bib47","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/bloodadvances.2024014970","article-title":"Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study","volume":"9","author":"Akhtar","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2025102810214826100_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"issue":"1","key":"2025102810214826100_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J Immunol"},{"issue":"12","key":"2025102810214826100_bib50","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1535-7163.MCT-23-0931","article-title":"Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens, and enhances T-cell anti-myeloma activity","volume":"23","author":"Rana","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2025102810214826100_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"2025102810214826100_bib52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025102810214826100_bib53","doi-asserted-by":"crossref","first-page":"fcab238","DOI":"10.1093\/braincomms\/fcab238","article-title":"Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis","volume":"3","author":"Klimas","year":"2021","journal-title":"Brain Commun"},{"issue":"1","key":"2025102810214826100_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","article-title":"Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia","volume":"17","author":"Sedloev","year":"16 2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025102810214826100_bib55","doi-asserted-by":"crossref","first-page":"19051","DOI":"10.1038\/s41598-021-98450-6","article-title":"Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells","volume":"11","author":"Benvenuto","year":"2021","journal-title":"Sci Rep"},{"issue":"16","key":"2025102810214826100_bib56","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","article-title":"Beyond BCMA: newer immune targets in myeloma","volume":"8","author":"Tan","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025102810214826100_bib57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"26","key":"2025102810214826100_bib58","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025102810214826100_bib59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025102810214826100_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"issue":"31","key":"2025102810214826100_bib61","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025102810214826100_bib62","doi-asserted-by":"crossref","first-page":"e432204","DOI":"10.1200\/EDBK_432204","article-title":"Charting the course: sequencing immunotherapy for multiple myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2025102810214826100_bib63","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2025102810214826100_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jcb.25617","article-title":"Targeting intrinsic and extrinsic vulnerabilities for the treatment of multiple myeloma","volume":"118","author":"Anreddy","year":"2017","journal-title":"J Cell Biochem"},{"issue":"8","key":"2025102810214826100_bib65","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/cells10081961","article-title":"A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics","volume":"10","author":"Awada","year":"2021","journal-title":"Cells"},{"issue":"7171","key":"2025102810214826100_bib66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"issue":"4","key":"2025102810214826100_bib67","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med"},{"issue":"6908","key":"2025102810214826100_bib68","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"issue":"5","key":"2025102810214826100_bib69","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"2025102810214826100_bib70","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"2025102810214826100_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","article-title":"Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma","volume":"48","author":"Zingone","year":"2011","journal-title":"Semin Hematol"},{"issue":"11","key":"2025102810214826100_bib72","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025102810214826100_bib73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple myeloma with t(11;14): impact of novel agents on outcome","volume":"13","author":"Puertas","year":"2023","journal-title":"Blood Cancer J"},{"issue":"15","key":"2025102810214826100_bib74","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2025102810214826100_bib75","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1038\/bcj.2015.91","article-title":"Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma","volume":"5","author":"Vu","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025102810214826100_bib76","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"2025102810214826100_bib77","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"2025102810214826100_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ajcp\/aqad103","article-title":"The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic","volume":"161","author":"Jew","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2025102810214826100_bib79","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"key":"2025102810214826100_bib80","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"1-2","key":"2025102810214826100_bib81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mrfmmm.2004.03.013","article-title":"Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis","volume":"569","author":"Bindra","year":"2005","journal-title":"Mutat Res"},{"issue":"4","key":"2025102810214826100_bib82","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","article-title":"Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma","volume":"23","author":"Manier","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"2025102810214826100_bib83","doi-asserted-by":"crossref","first-page":"1346211","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2025102810214826100_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"24","key":"2025102810214826100_bib85","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025102810214826100_bib86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"issue":"18","key":"2025102810214826100_bib87","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"issue":"15","key":"2025102810214826100_bib88","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2009-04-219436","article-title":"Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance","volume":"114","author":"Blotta","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2025102810214826100_bib89","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2025102810214826100_bib90","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025102810214826100_bib91","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2025102810214826100_bib92","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"2025102810214826100_bib93","doi-asserted-by":"crossref","first-page":"450291","DOI":"10.1155\/2013\/450291","article-title":"Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse","volume":"2013","author":"Gonz\u00e1lez","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"2025102810214826100_bib94","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","article-title":"What happens to regulatory T cells in multiple myeloma","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov"},{"issue":"1","key":"2025102810214826100_bib95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2025102810214826100_bib96","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"2025102810214826100_bib97","doi-asserted-by":"crossref","first-page":"663748","DOI":"10.3389\/fimmu.2021.663748","article-title":"Predictive role of immune profiling for survival of multiple myeloma patients","volume":"12","author":"Zhaoyun","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2025102810214826100_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"2025102810214826100_bib99","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"2025102810214826100_bib100","doi-asserted-by":"crossref","first-page":"1271807","DOI":"10.3389\/fonc.2023.1271807","article-title":"Immunomodulation of NK, NKT and B\/T cell subtypes in relapsed\/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival","volume":"13","author":"Prabhala","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"2025102810214826100_bib101","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s12026-024-09546-w","article-title":"Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity","volume":"72","author":"Shen","year":"2024","journal-title":"Immunol Res"},{"issue":"9","key":"2025102810214826100_bib102","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.3390\/cancers15092604","article-title":"Deep immune profiling of multiple myeloma at diagnosis and under lenalidomide maintenance therapy","volume":"15","author":"Luoma","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025102810214826100_bib103","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"2025102810214826100_bib104","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"2025102810214826100_bib105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.11897","article-title":"CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation","volume":"93","author":"Atanackovic","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2025102810214826100_bib106","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2025102810214826100_bib107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (review)","volume":"20","author":"Zhang","year":"2024","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"2025102810214826100_bib108","doi-asserted-by":"crossref","first-page":"e1474318","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-dose cyclophosphamide depletes circulating na\u00efve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"2025102810214826100_bib109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"issue":"9","key":"2025102810214826100_bib110","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025102810214826100_bib111","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"19","key":"2025102810214826100_bib112","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2025102810214826100_bib113","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"2025102810214826100_bib114","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2025102810214826100_bib115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2025102810214826100_bib116","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"issue":"29","key":"2025102810214826100_bib117","doi-asserted-by":"crossref","first-page":"26982","DOI":"10.18632\/oncotarget.4831","article-title":"Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"13","key":"2025102810214826100_bib118","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"30 2010","journal-title":"Blood"},{"key":"2025102810214826100_bib119","doi-asserted-by":"crossref","first-page":"816499","DOI":"10.3389\/fimmu.2021.816499","article-title":"Natural killer cells in the malignant niche of multiple myeloma","volume":"12","author":"Venglar","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"2025102810214826100_bib120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","article-title":"Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma","volume":"20","author":"Rueff","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025102810214826100_bib121","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-08-3807","article-title":"Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients","volume":"69","author":"M\u00e9nard","year":"2009","journal-title":"Cancer Res"},{"issue":"22","key":"2025102810214826100_bib122","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1158\/1078-0432.CCR-12-0531","article-title":"Stemness of B-cell progenitors in multiple myeloma bone marrow","volume":"18","author":"Boucher","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025102810214826100_bib123","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2025102810214826100_bib124","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025102810214826100_bib125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-024-01018-6","article-title":"Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025102810214826100_bib126","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025102810214826100_bib127","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"2025102810214826100_bib128","doi-asserted-by":"crossref","first-page":"609762","DOI":"10.3389\/fimmu.2021.609762","article-title":"Reprogramming immune cells for enhanced cancer immunotherapy: targets and strategies","volume":"12","author":"Dong","year":"2021","journal-title":"Front Immunol"},{"key":"2025102810214826100_bib129","doi-asserted-by":"crossref","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5134\/2416673\/blooda_adv-2025-016829-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5134\/2416673\/blooda_adv-2025-016829-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:31:35Z","timestamp":1761661895000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5134\/546232\/Molecular-and-immunological-determinants-of-long"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":129,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016829","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,15]]}}}